I can't imagine they would directly reference Gilead in an announcement unless they were pretty confident @davybabyk but i could be wrong.
in any case, once OASIS proves the concept of a CD19 targeting CAR T working with CF33, then you would think some of those players will move pretty quickly to get into the solid tumor market with their already approved drugs.
Imugene's current market cap is roughly AUD$800M. Blincyto alone does US$800M a year and Yescarta $1.5B.
Think things will move pretty quickly once the concept is proven.
GLTAH!
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-40
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $431.8M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.6¢ | $1.037M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1882949 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 399643 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |